APA (7th ed.) Citation

I, R., R, K., LH, M., K, S., L, W., P, S., . . . G, K. (2021). TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma. Frontiers in immunology, 12, 637146. https://doi.org/10.3389/fimmu.2021.637146

Chicago Style (17th ed.) Citation

I, Raphael, et al. "TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma." Frontiers in Immunology 12 (2021): 637146. https://doi.org/10.3389/fimmu.2021.637146.

MLA (9th ed.) Citation

I, Raphael, et al. "TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma." Frontiers in Immunology, vol. 12, 2021, p. 637146, https://doi.org/10.3389/fimmu.2021.637146.